Covaxin US FDA denies India’s Covaxin emergency use approval; seeks additional clinical trial data
Hyderabad/UNI:India’s indigenous Covid vaccine ‘Covaxin’ developed by Hyderabad-based Bharat Biotech (BB), will be delayed to launch in the US market as US Food and Drug Administration (FDA) asked ‘Ocugen Inc ‘ the US partner of the BB, to pursue a biological Applications (BLA) path for ‘Covaxin,’ which is full approval.
Bharat Biotech had earlier said it and Ocugen Inc, a US-based biopharmaceutical company, have entered into a definitive agreement to co-develop, supply, and commercialise, the India vaccine makers Covaxin for the USA market.
Ocugen, which is working towards the submission of the emergency use application (EUA) in the US, will simultaneously seek authorisation under interim order for emergency use in Canada.
According to Hyderabad-based vaccine maker on Friday, ‘Our US partner, Ocugen, has received a ‘recommendation ‘from the FDA to pursue a Biologics License Applications (BLA) path for COVAXIN®, which is full approval.
All applications have to follow the BLA process, which is the standard process for vaccines, it said.
Therefore, for BLA, data from an additional clinical trial will be required to support the marketing application submission for COVAXIN®, the company said ‘this process will extend our timelines’.
COVAXIN has received EUA’s from 14 countries with more than 50 countries in the process.
No vaccine manufactured or developed from India has ever received EUA or full license from USFDA, the company said.
It will be a Great Leap Forward for vaccine innovation and manufacturing from India when approved, it added.
The Pharma company also said with good herd immunity and a significant percentage of the population vaccinated, the USFDA had earlier communicated that no new emergency use authorization (EUA) would be approved for new Covid-19 vaccines.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
